- Home
- TENX vs BENF Comparison
TENX vs BENF Comparison
Compare TENX & BENF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | TENX | BENF |
|---|---|---|
| Founded | 1967 | 2003 |
| Country | United States | United States |
| Employees | N/A | 55 |
| Industry | Biotechnology: Pharmaceutical Preparations | Blank Checks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 56.2M | 53.1M |
| IPO Year | 2001 | N/A |
Fundamental Metrics
Financial Performance| Metric | TENX | BENF |
|---|---|---|
| Price | $11.75 | $3.44 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 3 | 0 |
| Target Price | ★ $29.67 | N/A |
| AVG Volume (30 Days) | ★ 605.5K | 264.9K |
| Earning Date | 05-15-2026 | 02-17-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $30.01 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $5.34 | $0.27 |
| 52 Week High | $18.38 | $9.96 |
Technical Indicators
Market Signals| Indicator | TENX | BENF |
|---|---|---|
| Relative Strength Index (RSI) | 37.17 | 53.85 |
| Support Level | $10.83 | $3.15 |
| Resistance Level | $14.15 | $4.84 |
| Average True Range (ATR) | 0.95 | 0.20 |
| MACD | -0.28 | 0.04 |
| Stochastic Oscillator | 7.00 | 97.83 |
Price Performance
Historical ComparisonAbout TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.
About BENF Beneficient
Beneficient is a technology-enabled financial services holding company that (together with its subsidiaries) provides simple, rapid, and cost-effective liquidity solutions to participants in the alternative asset industry through its end-to-end online platform, AltAccess. BCG's products and services are designed to meet the unmet needs of mid-to-high net-worth individual investors, small-to-midsize institutional investors, family offices, and fund general partners. Its bespoke liquidity solutions for otherwise illiquid alternative asset investments are delivered through proprietary technology and a financing and trust structure. It has three reportable segments consisting of Ben Liquidity, Ben Custody and Customer ExAlt Trusts.